The Effect Of Topical Anti-Glaucomatous Drops On Intraocular Pressure Changes In Patients Treated With Intravitreal Aflibercept

Yıl 2023, Cilt: 7 Sayı: 3, 263 - 266, 31.12.2023

Mehmet Coşkun

https://doi.org/10.30565/medalanya.1399134

Öz

Aim:The aim is to investigate the effect of using topical dorzolamide-timolol (DT) drops before intravitreal aflibercept (IVA) administration on intraocularpressure (IOP) changes.

Materials and Methods: Forty-five eyes of 45 patients with diabetic retinopathy and macular edema who received DT drops 1 hour before IVA were considered as group 1, and 45 eyes of 45 patients without DT drops were considered as group 2. Patients who had previously undergone intravitreal injection, intraocular surgery, and who used any eye drops were excluded from the study. IOP values were measured with Tonopen contact handheld tonometer before blepharostatinsertion (BBIOP), after blepharostat insertion (ABIOP) and at 1 minute after injection (AIIOP).

Results: There were 23 males and 22 females in group 1 and 22 males and 23 females in group 2 (p=0.96). The mean age was 55.23 ±7.53 years in group 1 and 55.70 ±9.78 years in group 2.(p=0. 97) In group 1, BBIOP was 18.12 ±4.18 mmHg, ABIOP 20.98 ±4.42 mmHg, AIIOP 43.20 ±15.80 mmHg, while in group 2, BBIOP 18.65 ±3.52 mmHg, ABIOP 22.80 ±3.90 mmHg, AIIOP 39.08 ±13.18 mmHg. The difference between AIIOP and BBIOP was 25.04 ±16.30 mmHg in group 1 and 20.36 ±13.82 mmHg in group 2, the difference was not statistically significant.(p=0.21) The difference between AIIOP and ABIOP was 22.32 ±16.48 mmHg in group 1 and 16.18 ±13.05 mmHg in group 2, the difference was statistically significant.(p=0.03).

Conclusion: In the group using topical DT drops before IVA administration, BBIOP and ABIOP values were lower, while AIIOP values were higher.

Anahtar Kelimeler

aflibercept, antiglaucomatous drop, ıntraokuler pressure

İntravitreal Aflibercept Uygulanan Hastalarda Topikal Antiglokomatöz Damlanın Göziçi Basıncı Değişimine Etkisi

Öz

Amaç: İntravitreal aflibersept(IVA) uygulaması öncesi topikal dorzolamid-timolol(DT) damla kullanımının göziçi basıncı(GİB) değişimine etkisinin incelenmesidir.

Gereç ve Yöntem:Diyabetik retinopati ve makula ödemi nedeniyle IVA uygulamasından 1 saat önce DT damlatılan 45 hastanın 45 gözü grup 1, DT damlatılmayan 45 hastanın 45 gözü grup 2 olarak kabul edildi.Daha önceden intravitreal enjeksiyon yapılan,göziçi cerrahisi geçiren ve herhangi bir göz damlası kullanan hastalar çalışmaya alınmadı. Enjeksiyon öncesi blefarosta takılmadan önce (ÖGİB), blefarosta takıldıktan sonra (BGİB), enjeksiyon sonrası 1. dakikada(EGİB) Tonopen kontakt el tonometresi ile GİB değerleri ölçüldü.

Bulgular: Grup 1 de 23 erkek, 22 kadın, grup 2 de 22 erkek, 23 kadın mevcut olup (p=0.96) yaş ortalaması grup 1 de 55.23 ±7.53 yıl, grup 2 de 55.70 ±9.78 yıldı.(p=0.97) Grup 1 de ÖGİB 18.12 ±4.18 mmHg, BGİB 20.98 ±4.42 mmHg, EGİB 43.20 ±15.80 mmHg iken grup 2 de ÖGİB 18.65 ±3.52 mmHg, BGİB 22.80 ±3.90 mmHg, EGİB 39.08 ±13.18 mmHg bulundu. Grup 1 de EGİB-ÖGİB farkı 25.04 ±16.30 mmHg, grup 2 de EGİB-ÖGİB farkı 20.36 ±13.82 mmHg bulunurken aradaki fark istatistiksel olarak anlamlı değildi.(p=0.21) Grup 1 de EGİB-BGİB farkı 22.32 ±16.48 mmHg, grup 2 de EGİB-BGİB farkı 16.18 ±13.05 mmHg bulundu, aradaki fark istatistiksel anlamlıydı.(p=0.03).

Sonuç: IVA uygulaması öncesi topikal DT damla kullanılan grupta ÖGİB ve BGİB değerleri daha düşükken,EGİB değerleri daha yüksek bulunmuştur.

Anahtar Kelimeler

aflibersept, antiglokomatöz damla, göz içi basıncı

Kaynakça

• 1. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol. 2011;56(2):95-113. doi: 10.1016/j.survophthal.2010.08.006.
• 2. Wong LJ, Desai RU, Jain A, Feliciano D, Moshfeghi DM, Sanislo SR, Blumenkranz MS. Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease. Retina. 2008;28(8):1151-8. doi: 10.1097/IAE.0b013e31817e100f.
• 3. Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hillemeier J. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye (Lond). 2009;23(1):181-5. doi: 10.1038/sj.eye.6702938.
• 4. Sharei V, Höhn F, Köhler T, Hattenbach LO, Mirshahi A. Course of intraocular pressure after intravitreal injection of 0.05 mL ranibizumab (Lucentis). Eur J Ophthalmol. 2010;20(1):174-9. doi: 10.1177/112067211002000124.
• 5. Kotliar K, Maier M, Bauer S, Feucht N, Lohmann C, Lanzl I. Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model. Acta Ophthalmol Scand. 2007;85(7):777-81. doi: 10.1111/j.1600-0420.2007.00939.x.
• 6. Gismondi M, Salati C, Salvetat ML, Zeppieri M, Brusini P. Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure. J Glaucoma. 2009;18(9):658-61. doi: 10.1097/IJG.0b013e31819c4893.
• 7. Höhn F, Mirshahi A. Impact of injection techniques on intraocular pressure (IOP) increase after intravitreal ranibizumab application. Graefes Arch Clin Exp Ophthalmol. 2010;248(10):1371-5. doi: 10.1007/s00417-010-1382-1.
• 8. Whitacre MM, Stein R. Sources of error with use of Goldmann-type tonometers. Surv Ophthalmol. 1993;38(1):1-30. doi: 10.1016/0039-6257(93)90053-a.
• 9. Güngör İ,Turgut Coban D,Beden Ü,Arıtürk N,Öge İ. Tonopen ile Goldmann aplanasyon tonometresine en yakın ölçümlerin elde eldilmesinde yöntemler. MN Oftalmoloji. 2007; 14(4): 241 - 244.
• 10. Yildiz, I., Altan, C., Cakmak, S., Genc, S., Yildirim, Y., & Agca, A., (2022). Comparison of Intraocular Pressure Measurements With Goldmann Applanation Tonometry, Tonopen XL, and Pascal Dynamic Contour Tonometry in Patients With Descemet Membrane Endothelial Keratoplasty. Journal of Glaucoma,2022;31(11): 909-914. 11. Yannuzzi NA, Patel SN, Bhavsar KV, Sugiguchi F, Freund KB. Predictors of sustained intraocular pressure elevation in eyes receiving intravitreal anti-vascular endothelial growth factor therapy. Am J Ophthalmol. 2014;158(2):319-327.e2. doi: 10.1016/j.ajo.2014.04.029.
• 12. Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol. 2008;146(6):930-4.e1. doi: 10.1016/j.ajo.2008.07.007.
• 13. Frenkel MP, Haji SA, Frenkel RE. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections. Arch Ophthalmol. 2010;128(12):1523-7. doi: 10.1001/archophthalmol.2010.297.
• 14. Theoulakis PE, Lepidas J, Petropoulos IK, Livieratou A, Brinkmann CK, Katsimpris JM. Effect of brimonidine/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab. Klin Monbl Augenheilkd. 2010;227(4):280-4. doi: 10.1055/s-0029-1245201.